Safety of hydroxychloroquine for treatment or prevention of SARS‐CoV‐2 infection: A rapid systematic review and meta‐analysis of randomized clinical trials

Immunity, Inflammation and Disease

Alberto Enrico Maraolo¹  Adriano Grossi² 

[1] First Division of Infectious Diseases Cotugno Hospital Naples Italy;Section of Hygiene, University Department of Life Sciences and Public Health Università Cattolica del Sacro Cuore Roma Italy;

关键词: COVID‐19;    hydroxychloroquine;    meta‐analysis;    randomized controlled trials;    safety;    SARS‐CoV‐2;   

DOI  :  10.1002/iid3.374

来源: DOAJ

【 摘 要 】

Abstract Introduction Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID‐19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. Methods In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID‐19 randomized clinical trials. Results Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14–9.45. Conclusion Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID‐19, especially in the light of unproved clinical benefit.

【 授权许可】

Unknown